Charles River Laboratories to Present at Jefferies Global Healthcare Conference
Charles River Laboratories announced its participation in the upcoming Jefferies Global Healthcare Conference.
Stocks · News reference
Charles River Laboratories will buy Frontage's bioanalysis unit for $470 million in cash to expand its clinical drug testing scale.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Charles River Laboratories announced its participation in the upcoming Jefferies Global Healthcare Conference.
Intermonte has increased its target price for Carel Industries from 37 to 38 euros while maintaining an 'outperform' rating.
Banca Akros has upgraded its recommendation for Carel Industries to 'buy' from 'accumulate' and raised the target price to 35 euros.
Charles River Laboratories and Toxys have expanded their partnership to increase access to ToxTracker and ReproTracker for toxicity assessment.
TD Cowen has raised its price target for Charles River Laboratories International, Inc. from $325 to $388 while maintaining a Buy rating.
Charles River Laboratories International, Inc. has entered into definitive agreements to acquire the bioanalysis and drug metabolism and pharmacokinetics (DMPK) businesses of Frontage Laboratories for $470 million in cash.